Astellas & Bayer double up in the ‘Most valuable patient initiative’ category at eyeforpharma Barcelona Awards

Both Astellas Pharma & Bayer Healthcare have two projects each in the shortlist for ‘Most valuable patient initiative’ category at the eyeforpharma Barcelona Awards; indicating both companies’ commitment to patient-centric innovation.

The two Astellas projects from the UK focus on urology & patients suffering from over-active bladder, while Bayer’s initiatives use technology to tackle contraceptive use in Turkey and Rosacea sufferers in the US. Also shortlisted are MSD India for their SPARSH Diabetes programme, and Pfizer Hong Kong’s more wide-reaching Kezzler ‘PASS’ project.

The names of the six shortlisted projects for this award, selected from over 100 nominations, were identified as the front-runners in patient innovation and value creation in the industry and were released as part of the much-anticipated list of finalists for the inaugural eyeforpharma Barcelona Awards.

The judges favoured projects which could demonstrate real patient-experience improvement and those which showed a real understanding of culture and patient-need. Of the Bayer ‘Don’t Leave Love to Luck’ app judges agreed that the project was “a great socially responsible solution” and commended the “creative engagement” while Astellas was praised for tackling “taboo” subjects in a “targeted and relevant manner”.

A comprehensive list of finalists and their project videos can be found online here: http://www.eyeforpharma.com/barcelona/awards-finalists.php

Winners will be announced at the very first eyeforpharma Barcelona Awards, sponsored by IMS Health, on Tuesday 18th March at the CCIB, Barcelona from 7.30pm, as part of the largest gathering of pharma executives, eyeforpharma Barcelona. The evening will be attended by the top 200 VIPs from the pharma industry.

For more information contact Awards Manager, Chloe Leighton on chloe@eyeforpharma.com or visit www.eyeforpharma.com/barcelona/awards